We believe that this transaction offers a compelling value proposition for our clients:
- Clients will be able to take advantage of our broader portfolio as WIL Research’s expertise in specialty safety assessment services and bioanalysis, as well as Contract Development and Manufacturing (CDMO) services are added.
- WIL Research provides safety assessment capacity with strategically located facilities to support current and future global client requirements, including continental Europe.
This acquisition provides enhanced services, capabilities and capacity for the growing biotechnology client base. Together we provide clients the opportunity to partner with a single fully integrated CRO across the drug discovery and development continuum.